Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Year : 2017  |  Volume : 30  |  Issue : 3  |  Page : 693-699

Serum peroxiredoxin-3 as a useful biomarker for detection of hepatocellular carcinoma

1 Department of Internal Medicine, Faculty of Medicine, Menoufia University, Menoufia, Egypt
2 Department of Hepatology, National liver Institute, Menoufia University, Menoufia, Egypt
3 Department of Biochemistry, Faculty of Medicine, Menoufia University, Menoufia, Egypt
4 Cairo Fatemic Hospital, Cairo, Egypt

Correspondence Address:
Mohamed H. S. Al-Karafy
Cairo, 11511
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/1110-2098.218277

Rights and Permissions

Objective The aim of this study is to evaluate serum peroxiredoxin-3 (PRDX3) as a noninvasive serum marker for the diagnosis of hepatocellular carcinoma (HCC). Background Early diagnosis of HCC is the most important step in successful treatment. However, it is usually rare because of the lack of a highly sensitive and specific biomarker so that the HCC is usually fatal within a few months after diagnosis. PRDX3 is a c-Myc target gene that is required for mitochondrial homeostasis and neoplastic transformation. In our study, we attempted to evaluate the value of PRDX3 as a useful serum biomarker for the detection of HCC. Patients and methods PRDX3, α-fetoprotein (AFP), and other biochemical parameters were measured in serum samples from 50 patients. They were subdivided into three groups: 20 patients with cirrhosis and HCC (group I), 20 patients with liver cirrhosis (LC) without HCC (group II), and 10 healthy controls (group III). Correlations between serum PRDX3 expression and clinicopathological variables were analyzed. Results Serum PRDX3 was significantly higher in HCC patients than in the LC and healthy control groups. The sensitivity and specificity of serum PRDX3 for the diagnosis of HCC were 84.2 and 79.8%, respectively, at a cutoff of 162 ng/ml and the area under the curve was 0.877 compared with that of AFP (0.721) with a sensitivity of 70.1% and a specificity of 60%. Moreover, serum PRDX3 expression was strongly associated with AFP levels and focal lesion size. Conclusion Serum PRDX3 level, at a cutoff value of 162 ng/ml, could be a valuable marker for the detection of HCC in patients with LC.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded59    
    Comments [Add]    

Recommend this journal